Cardlytics Inc. (NASDAQ:CDLX) finished Friday with a subtraction of -$2.27 to close at $65.37, a downside of -3.36 percent. An average of 526,380 shares of common stock have been traded in the last five days. There was a gain of $4.29 in the past week, and it reached a new high 14 times over the past 12 months. The last 20 days have seen an average of 407,185 shares traded, while the 50-day average volume stands at 420,520.
CDLX stock has decreased by -1.25% in the last month. The company shares reached their 1-month lowest point of $56.06 on 01/10/22. With the stock rallying to its 52-week high on 01/13/22, shares of the company touched a low of $56.06 and a high of $161.47 in 52 weeks. It has reached a new high 3 times so far this year and lost -1.09% or -$0.72 in price. In spite of this, the price is down -59.52% from the 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
2 days have passed since Cardlytics Inc. (CDLX) last reported insider trading activity. SOMERS KIRK, who is Chief Legal & Privacy Officer, most recently acquired $1,000 shares at $67.97 per share on Jan 13. In this transaction, the insider spent $67,970. Chief Financial Officer, Christiansen Andrew, disposed of 250 shares at a price of $61.02 on Jan 10. The insider now owns more than $15,255 worth of shares. Prior to that, Director Grimes Scott D. went on to Sale 6,000 shares at $62.79 each on Dec 20. An amount of $376,719 was transacted.
Cardlytics Inc. (CDLX) has a trailing price-to-earnings (P/E) ratio of 24.93 for the broader industry and 24.47 for the sector. The stock’s beta is 2.38. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.14, the price-to-book (PB) ratio at 3.14.
The quick ratio of Cardlytics Inc. for the three months ended September 29 was 1.20, and the current ratio was 1.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.26 and a total debt to equity ratio of 0.26 for the quarter ending September 29. Cardlytics Inc.’s EBITDA margin for the year ending September 29 is -22.20%, while its operating margin for the same period stands at -52.60%. Its gross profit as reported stood at $63.27 million compared to revenue of $186.89 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Cardlytics Inc.’s return on assets was -14.50%. For the broader industry, ROE averaged 3.84 over the past year.
For the three-month period that ended September 29, Cardlytics Inc. had $181.73 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$44.53 million in the quarter, while revenues of -$47.31 million were grew 55.63%. The analyst consensus anticipated Cardlytics Inc.’s latest quarter earnings to come in at -$0.54 per share, but it turned out to be -$0.33, a 38.90% surprise. For the quarter, EBITDA amounted to -$26.62 million. Shareholders own equity worth $33.27 million.
From a technical analysis perspective, let’s take a brief look at Cardlytics Inc. (CDLX) price momentum. RSI 9-day as of the close on 14 January was 50.66%, suggesting the stock is Neutral, with historical volatility in this time frame at 84.68%.
As of today, CDLX’s price is $64.91 +7.02% or $4.29 from its 5-day moving average. CDLX is currently trading +2.72% higher than its 20-day SMA and -25.12% lower than its 100-day SMA. However, the stock’s current price level is -26.17% below the SMA50 and -45.18% below the SMA200.
The stochastic %K and %D were 72.50% and 65.97%, respectively, and the average true range (ATR) was 5.28. With the 14-day stochastic at 59.49% and the average true range at 5.03, the RSI (14) stands at 48.49%. The stock has reached 3.52 on the 9-day MACD Oscillator while the 14-day reading was at 2.59.
Needham launched coverage on Cardlytics Inc. (NASDAQ: CDLX) in its analyst report released on June 18, 2021. The firm assigned the stock a a Buy rating.
What is CDLX’s price target for the next 12 months?
Analysts predict a range of price targets between $73.00 and $120.00, with a median target of $95.00. Taking a look at these predictions, the average price target given by analysts for Cardlytics Inc. (CDLX) stock is $95.75.